Cencora ( (COR) ) just unveiled an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cencora, Inc. reported significant growth in its fiscal 2024 results, boasting a 14.7% increase in fourth-quarter revenue to $79.1 billion and a 12.1% rise for the year to $294.0 billion. Despite a drop in GAAP diluted EPS to $0.02 in the fourth quarter, adjusted EPS saw a robust 16.8% rise to $3.34. The company enhanced its strategic pharmaceutical distribution capabilities and expanded its specialty services with the acquisition of Retina Consultants of America. Cencora remains committed to growth and long-term value creation for stakeholders.
See more data about COR stock on TipRanks’ Stock Analysis page.
